Loading...

Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Endocrinol Metab (Seoul)
Main Authors: Moon, Shinje, Lee, Jibeom, Chung, Hye Soo, Kim, Yoon Jung, Yu, Jae Myung, Yu, Sung Hoon, Oh, Chang-Myung
Format: Artigo
Sprog:Inglês
Udgivet: Korean Endocrine Society 2021
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8258332/
https://ncbi.nlm.nih.gov/pubmed/34139800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3803/EnM.2020.934
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!